What question did this study set out to answer?

To evaluate the efficacy and safety of carfilzomib-augmented high-dose melphalan in multiple myeloma patients undergoing ASCT.

December 8, 2025BloodOpen Access

Carfilzomib Augmented with high-dose melphalan conditioning regimen Enhances Response in patients with multiple myeloma eligible for ASCT：an investigator-initiated, prospective, multicenter study

View Full Paper

Ask AI

Bookmark

Authors

Investigator-initiated trial shows 100% VGPR in multiple myeloma, indicating improved outcomes for ASCT.

To evaluate the efficacy and safety of carfilzomib-augmented high-dose melphalan in multiple myeloma patients undergoing ASCT.
Prospective, multicenter, single-arm study across three centers in China
Inclusion of newly diagnosed transplant-eligible multiple myeloma patients aged ≥18 years
Conditioning regimen included 27 mg/m²/day carfilzomib and 200 mg/m² high-dose melphalan
Assessment of efficacy endpoints such as VGPR, adverse events, engraftment kinetics, PFS, and OS
100% of patients achieved ≥ VGPR at three months post-ASCT, up from 85.7% pre-ASCT
Complete response rate increased to 65.7% from 40.0% pre-ASCT
Median time to neutrophil engraftment was 11 days, and platelet engraftment was 13 days with no poor engraftment
No grade ≥3 adverse events; manageable grade 1-2 gastrointestinal issues reported

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark